-
Publication Venue For
-
Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)..
25:1473-1484.
2023
-
Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100..
23:1983-1988.
2021
-
Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials..
23:1101-1110.
2021
-
Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial..
22:2493-2498.
2020
-
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL..
22:798-806.
2020
-
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study)..
21:1990-1995.
2019
-
Role of vagal activation in postprandial glucose metabolism after gastric bypass in individuals with and without hypoglycaemia..
21:1513-1517.
2019
-
Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers..
21:1223-1236.
2019
-
Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015..
21:854-865.
2019
-
Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS..
20:2379-2388.
2018
-
Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)..
20:1732-1739.
2018
-
Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)..
20:1427-1434.
2018
-
Beta-cell sensitivity to glucose is impaired after gastric bypass surgery..
20:872-878.
2018
-
Effects of an energy-restricted low-carbohydrate, high unsaturated fat/low saturated fat diet versus a high-carbohydrate, low-fat diet in type 2 diabetes: A 2-year randomized clinical trial..
20:858-871.
2018
-
Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors)..
20:233-237.
2018
-
Metabolomics applied to islet nutrient sensing mechanisms..
19 Suppl 1:90-94.
2017
-
Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial..
19:78-86.
2017
-
Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes..
18:1138-1142.
2016
-
Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin..
18:654-662.
2016
-
GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects..
17:1007-1010.
2015
-
Unsupervised home use of an overnight closed-loop system over 3-4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes..
17:452-458.
2015
-
Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)..
17:395-402.
2015
-
Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes..
17:170-178.
2015
-
Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study..
16:1265-1268.
2014
-
Weight changes in obese adults 6-months after discontinuation of double-blind zonisamide or placebo treatment..
16:766-768.
2014
-
Two diets with different haemoglobin A1c and antiglycaemic medication effects despite similar weight loss in type 2 diabetes..
16:90-93.
2014
-
Low HDL predicts differential blood pressure effects from two weight-loss approaches: a secondary analysis of blood pressure from a randomized, clinical weight-loss trial..
14:375-378.
2012
-
The role of dysregulated glucagon secretion in type 2 diabetes..
13 Suppl 1:126-132.
2011
-
Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder..
13:726-735.
2011
-
Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials..
13:615-628.
2011
-
Pharmaceutical interventions for obesity: a public health perspective..
13:490-497.
2011
-
Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome..
12:983-993.
2010
-
A link between endoplasmic reticulum stress-induced β-cell apoptosis and the group VIA Ca2+-independent phospholipase A2 (iPLA2β)..
12 Suppl 2:93-98.
2010
-
Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia..
11:855-864.
2009
-
Impaired glucose tolerance, but not impaired fasting glucose, is associated with retinopathy in Japanese population: the Funagata study..
10:514-515.
2008